The rise of copyright’s blockbuster initially fueled a boom for pharma, however recent changes present a murky outlook for shareholders. Generic alternatives are eating into revenue, and continued legal battles add https://diegocvbr859205.win-blog.com/22442152/sildenafil-and-pharma-a-precarious-investment